Key role for EphB2 receptor in kidney fibrosis.


Journal

Clinical science (London, England : 1979)
ISSN: 1470-8736
Titre abrégé: Clin Sci (Lond)
Pays: England
ID NLM: 7905731

Informations de publication

Date de publication:
17 09 2021
Historique:
received: 21 06 2021
revised: 24 08 2021
accepted: 27 08 2021
pubmed: 1 9 2021
medline: 15 12 2021
entrez: 31 8 2021
Statut: ppublish

Résumé

Erythropoietin producing hepatocellular (Eph)-Eph receptor interacting (Ephrin) receptor-ligand signaling has been implicated in the development of tissue fibrosis, though it has not been well defined in the kidney. We detected substantial up-regulation of expression and phosphorylation of the EphB2 receptor tyrosine kinase in fibrotic kidney tissue obtained both from mice subjected to the unilateral renal ischemia-reperfusion (IR) model at 14 days and in patients suffering from chronic kidney disease (CKD). Knockout (KO) mice lacking EphB2 expression exhibited a normal renal structure and function, indicating no major role for this receptor in kidney development or action. Although IR injury is well-known to cause tissue damage, fibrosis, and renal dysfunction, we found that kidneys from EphB2KO mice showed much less renal tubular injury and retained a more preserved renal function. IR-injured kidneys from EphB2 KOs exhibited greatly reduced fibrosis and inflammation compared with injured wildtype (WT) littermates, and this correlated with a significant reduction in renal expression of profibrotic molecules, inflammatory cytokines, NADPH oxidases, and markers for cell proliferation, tubular epithelial-to-mesenchymal transition (EMT), myofibroblast activation, and apoptosis. A panel of 760 fibrosis-associated genes were further assessed, revealing that 506 genes in WT mouse kidney following IR injury changed their expression. However, 70.9% of those genes were back to or close to normal in expression when EphB2 was deleted. These data indicate that endogenous EphB2 expression and signaling are abnormally activated after kidney injury and subsequently contribute to the development of renal fibrosis via regulation of multiple profibrotic pathways.

Identifiants

pubmed: 34462781
pii: 229704
doi: 10.1042/CS20210644
pmc: PMC8433383
doi:

Substances chimiques

Inflammation Mediators 0
EPHB2 protein, human EC 2.7.10.1
Ephb2 protein, mouse EC 2.7.10.1
Receptor, EphB2 EC 2.7.10.1

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

2127-2142

Subventions

Organisme : NIDDK NIH HHS
ID : R01 DK123727
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR002538
Pays : United States

Informations de copyright

© 2021 The Author(s).

Références

Cell. 2002 Oct 18;111(2):251-63
pubmed: 12408869
Curr Rheumatol Rep. 2019 Apr 12;21(6):23
pubmed: 30980212
Gastroenterology. 2009 Jul;137(1):145-55, 155.e1-3
pubmed: 19332065
PLoS Med. 2008 Mar 4;5(3):e62
pubmed: 18318599
Front Immunol. 2019 Jul 04;10:1473
pubmed: 31333644
Sci Rep. 2018 Feb 7;8(1):2532
pubmed: 29416088
J Am Soc Nephrol. 2001 Dec;12(12):2673-2682
pubmed: 11729236
Am J Physiol Endocrinol Metab. 2017 Nov 1;313(5):E563-E576
pubmed: 28811292
Circulation. 2017 Aug 8;136(6):566-582
pubmed: 28487392
Exp Ther Med. 2018 Mar;15(3):2219-2227
pubmed: 29456630
Proc Natl Acad Sci U S A. 1997 Sep 30;94(20):10925-30
pubmed: 9380736
Antioxid Redox Signal. 2000 Winter;2(4):811-20
pubmed: 11213485
Kidney Int. 2009 Sep;76(5):546-56
pubmed: 19571790
Antioxid Redox Signal. 2011 Sep 15;15(6):1583-606
pubmed: 21473702
Hepatology. 2015 Sep;62(3):900-14
pubmed: 25784101
J Cell Sci. 2006 Feb 1;119(Pt 3):559-70
pubmed: 16443753
Am J Physiol Renal Physiol. 2018 Sep 1;315(3):F558-F571
pubmed: 29873514
Clin Chem. 2004 Mar;50(3):490-9
pubmed: 14726470
Cell Death Dis. 2021 Apr 30;12(5):432
pubmed: 33931588
Mech Dev. 2003 Apr;120(4):511-6
pubmed: 12676328
J Am Soc Nephrol. 2013 Mar;24(4):559-72
pubmed: 23492730
PLoS One. 2016 Mar 23;11(3):e0152153
pubmed: 27007127
Nature. 2001 Dec 20-27;414(6866):933-8
pubmed: 11780069
Clin Sci (Lond). 2018 Jun 28;132(12):1345-1363
pubmed: 29848510
Circ Res. 2017 Sep 1;121(6):617-627
pubmed: 28743805
J Am Soc Nephrol. 2008 Feb;19(2):329-38
pubmed: 18216319
Mol Cells. 2015 Jan 31;38(1):14-9
pubmed: 25475547
J Immunol Res. 2018 Sep 6;2018:2180373
pubmed: 30271792
Cell. 1996 Jul 12;86(1):35-46
pubmed: 8689685
Nature. 1996 Oct 24;383(6602):722-5
pubmed: 8878483
Cell Rep. 2015 Nov 17;13(7):1380-1395
pubmed: 26549443
Kidney Int. 2007 Oct;72(8):954-64
pubmed: 17667985
Curr Protoc Mol Biol. 2011 Apr;Chapter 25:Unit25B.10
pubmed: 21472696
J Biol Chem. 2002 Feb 8;277(6):3823-8
pubmed: 11713248
Adv Cancer Res. 2012;114:21-57
pubmed: 22588055
Front Med (Lausanne). 2020 Mar 12;7:65
pubmed: 32226789
Am J Physiol Renal Physiol. 2011 Dec;301(6):F1334-45
pubmed: 21921025
Cell. 2008 Apr 4;133(1):38-52
pubmed: 18394988

Auteurs

Zhimin Huang (Z)

Department of Internal Medicine, Division of Nephrology and Hypertension, University of Utah Health Science, Salt Lake City, UT, U.S.A.
Department of Internal Medicine, Division of Nephrology, Nanjing Medical University, Jiangsu Province Hospital, Nanjing, China.

Simeng Liu (S)

Department of Internal Medicine, Division of Nephrology and Hypertension, University of Utah Health Science, Salt Lake City, UT, U.S.A.

Anna Tang (A)

Department of Internal Medicine, Division of Nephrology and Hypertension, University of Utah Health Science, Salt Lake City, UT, U.S.A.

Laith Al-Rabadi (L)

Department of Internal Medicine, Division of Nephrology and Hypertension, University of Utah Health Science, Salt Lake City, UT, U.S.A.

Mark Henkemeyer (M)

Department of Neuroscience, University of Texas Southwestern Medical Center, Dallas, TX, U.S.A.

Patrice N Mimche (PN)

Department of Pathology, Division of Microbiology and Immunology, Molecular Medicine Program, University of Utah Health Science, Salt Lake City, UT, U.S.A.

Yufeng Huang (Y)

Department of Internal Medicine, Division of Nephrology and Hypertension, University of Utah Health Science, Salt Lake City, UT, U.S.A.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH